Targeting genomic receptors in voided urine for confirmation of benign prostatic hyperplasia
Abstract Objectives The objective of this study is to validate a hypothesis that a non‐invasive optical imaging assay targeting genomic VPAC receptors on malignant cells shed in voided urine will represent either benign prostatic hyperplasia (BPH) or prostatic cancer (PCa). Risk for BPH in men 50–70...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-07-01
|
| Series: | BJUI Compass |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/bco2.362 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850134971640971264 |
|---|---|
| author | Mathew Thakur Vivek S. Tomar Emma Dale Leonard G. Gomella Charalambos Solomides Oleksandr Kolesnikov Scott W. Keith Hector T. Navarro Olivia Dahlgren Michael Chaga Edouard J. Trabulsi |
| author_facet | Mathew Thakur Vivek S. Tomar Emma Dale Leonard G. Gomella Charalambos Solomides Oleksandr Kolesnikov Scott W. Keith Hector T. Navarro Olivia Dahlgren Michael Chaga Edouard J. Trabulsi |
| author_sort | Mathew Thakur |
| collection | DOAJ |
| description | Abstract Objectives The objective of this study is to validate a hypothesis that a non‐invasive optical imaging assay targeting genomic VPAC receptors on malignant cells shed in voided urine will represent either benign prostatic hyperplasia (BPH) or prostatic cancer (PCa). Risk for BPH in men 50–70 years old is 50–70% and PCa is 17%. BPH and PCa can coexist in 20% of men with BPH. Most commonly practiced methods to diagnose BPH do not distinguish BPH from PCa. Patients (or Materials) and Methods Males with BPH (N = 97, 60.8 ± 6.3 years, prostate‐specific antigen 0.7 ± 0.4 ng/mL) and without oncologic disease (N = 35, 63.4 ± 5.8 years, prostate‐specific antigen < 1.5 ng/mL) signed informed consent form and provided voided urine. Urine was cytocentrifuged, cells collected on glass slide, fixed, treated with VPAC specific fluorophore TP4303 (Kd 3.1 × 10−8M), washed, incubated with DAPI and observed using a fluorescence microscope. Cells with no VPAC did not fluoresce (BPH) and those with VPAC had red‐orange fluorescence (PCa). Real‐time polymerase chain reaction analyses for VPAC and NKX3.1 assay for cell origin were performed. Results Eighty‐seven subjects were negative for VPAC expression. Positive VPAC expression was noted in 10 subjects. Patient chart review for clinical data on these 10 VPAC positive subjects showed five had nephrolithiasis, three had renal cysts, one had prostatitis and one was being treated with finasteride. Real‐time polymerase chain reaction analysis‐VPAC expressions for 7 normal and 12 BPH subjects were 1.31 ± 1.26 and 0.94 ± 0.89, respectively (P = 0.46). NKX3.1 showed cells of prostate origin for finasteride‐treated patient. Specificity for VPAC urine assay for excluding prostate cancer in this BPH cohort was 88.5%, positive predictive value 0.00% and negative predictive value 100%. Conclusion VPAC assay may contribute extensively for BPH diagnosis and warrant continued investigation. |
| format | Article |
| id | doaj-art-eba6f254466f4e338bfd77aa902133bd |
| institution | OA Journals |
| issn | 2688-4526 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | BJUI Compass |
| spelling | doaj-art-eba6f254466f4e338bfd77aa902133bd2025-08-20T02:31:34ZengWileyBJUI Compass2688-45262024-07-015778979410.1002/bco2.362Targeting genomic receptors in voided urine for confirmation of benign prostatic hyperplasiaMathew Thakur0Vivek S. Tomar1Emma Dale2Leonard G. Gomella3Charalambos Solomides4Oleksandr Kolesnikov5Scott W. Keith6Hector T. Navarro7Olivia Dahlgren8Michael Chaga9Edouard J. Trabulsi10Department of Radiology, Urology, Radiation Oncology and S. Kimmel Cancer Center Thomas Jefferson University Philadelphia Pennsylvania USADepartment of Radiology Thomas Jefferson University Philadelphia Pennsylvania USADepartment of Radiology Thomas Jefferson University Philadelphia Pennsylvania USADepartment of Urology and S. Kimmel Cancer Center Thomas Jefferson University Philadelphia Pennsylvania USADepartment of Pathology and Genomic Medicine Thomas Jefferson University Philadelphia Pennsylvania USADepartment of Urology and S. Kimmel Cancer Center Thomas Jefferson University Philadelphia Pennsylvania USADivision of Biostatistics and S. Kimmel Cancer Center Thomas Jefferson University Philadelphia Pennsylvania USADepartment of Radiology Thomas Jefferson University Philadelphia Pennsylvania USADepartment of Urology Thomas Jefferson University Philadelphia Pennsylvania USADepartment of Radiology Thomas Jefferson University Philadelphia Pennsylvania USADepartment of Urology Jefferson Einstein Medical Center and Thomas Jefferson University Philadelphia Pennsylvania USAAbstract Objectives The objective of this study is to validate a hypothesis that a non‐invasive optical imaging assay targeting genomic VPAC receptors on malignant cells shed in voided urine will represent either benign prostatic hyperplasia (BPH) or prostatic cancer (PCa). Risk for BPH in men 50–70 years old is 50–70% and PCa is 17%. BPH and PCa can coexist in 20% of men with BPH. Most commonly practiced methods to diagnose BPH do not distinguish BPH from PCa. Patients (or Materials) and Methods Males with BPH (N = 97, 60.8 ± 6.3 years, prostate‐specific antigen 0.7 ± 0.4 ng/mL) and without oncologic disease (N = 35, 63.4 ± 5.8 years, prostate‐specific antigen < 1.5 ng/mL) signed informed consent form and provided voided urine. Urine was cytocentrifuged, cells collected on glass slide, fixed, treated with VPAC specific fluorophore TP4303 (Kd 3.1 × 10−8M), washed, incubated with DAPI and observed using a fluorescence microscope. Cells with no VPAC did not fluoresce (BPH) and those with VPAC had red‐orange fluorescence (PCa). Real‐time polymerase chain reaction analyses for VPAC and NKX3.1 assay for cell origin were performed. Results Eighty‐seven subjects were negative for VPAC expression. Positive VPAC expression was noted in 10 subjects. Patient chart review for clinical data on these 10 VPAC positive subjects showed five had nephrolithiasis, three had renal cysts, one had prostatitis and one was being treated with finasteride. Real‐time polymerase chain reaction analysis‐VPAC expressions for 7 normal and 12 BPH subjects were 1.31 ± 1.26 and 0.94 ± 0.89, respectively (P = 0.46). NKX3.1 showed cells of prostate origin for finasteride‐treated patient. Specificity for VPAC urine assay for excluding prostate cancer in this BPH cohort was 88.5%, positive predictive value 0.00% and negative predictive value 100%. Conclusion VPAC assay may contribute extensively for BPH diagnosis and warrant continued investigation.https://doi.org/10.1002/bco2.362BPH diagnosisliquid biopsy and non‐invasive BPH diagnosisvoided urine assayVPAC receptor assay |
| spellingShingle | Mathew Thakur Vivek S. Tomar Emma Dale Leonard G. Gomella Charalambos Solomides Oleksandr Kolesnikov Scott W. Keith Hector T. Navarro Olivia Dahlgren Michael Chaga Edouard J. Trabulsi Targeting genomic receptors in voided urine for confirmation of benign prostatic hyperplasia BJUI Compass BPH diagnosis liquid biopsy and non‐invasive BPH diagnosis voided urine assay VPAC receptor assay |
| title | Targeting genomic receptors in voided urine for confirmation of benign prostatic hyperplasia |
| title_full | Targeting genomic receptors in voided urine for confirmation of benign prostatic hyperplasia |
| title_fullStr | Targeting genomic receptors in voided urine for confirmation of benign prostatic hyperplasia |
| title_full_unstemmed | Targeting genomic receptors in voided urine for confirmation of benign prostatic hyperplasia |
| title_short | Targeting genomic receptors in voided urine for confirmation of benign prostatic hyperplasia |
| title_sort | targeting genomic receptors in voided urine for confirmation of benign prostatic hyperplasia |
| topic | BPH diagnosis liquid biopsy and non‐invasive BPH diagnosis voided urine assay VPAC receptor assay |
| url | https://doi.org/10.1002/bco2.362 |
| work_keys_str_mv | AT mathewthakur targetinggenomicreceptorsinvoidedurineforconfirmationofbenignprostatichyperplasia AT vivekstomar targetinggenomicreceptorsinvoidedurineforconfirmationofbenignprostatichyperplasia AT emmadale targetinggenomicreceptorsinvoidedurineforconfirmationofbenignprostatichyperplasia AT leonardggomella targetinggenomicreceptorsinvoidedurineforconfirmationofbenignprostatichyperplasia AT charalambossolomides targetinggenomicreceptorsinvoidedurineforconfirmationofbenignprostatichyperplasia AT oleksandrkolesnikov targetinggenomicreceptorsinvoidedurineforconfirmationofbenignprostatichyperplasia AT scottwkeith targetinggenomicreceptorsinvoidedurineforconfirmationofbenignprostatichyperplasia AT hectortnavarro targetinggenomicreceptorsinvoidedurineforconfirmationofbenignprostatichyperplasia AT oliviadahlgren targetinggenomicreceptorsinvoidedurineforconfirmationofbenignprostatichyperplasia AT michaelchaga targetinggenomicreceptorsinvoidedurineforconfirmationofbenignprostatichyperplasia AT edouardjtrabulsi targetinggenomicreceptorsinvoidedurineforconfirmationofbenignprostatichyperplasia |